Interested in the evolution of how we share and curate our science? For those coming to CICON24, check out @beiyun_liu and this poster. For those not there, try this out, participate, enjoy helping science and your colleagues move forward: https://t.co/KOflhzoJw9

🙏RT 📅Abstract deadline DC2024 Barcelona 30th May 🚨 SUBMIT NOW 👇 https://t.co/ujuSt2Dk5q 🔬34 short talks + posters!!! 🔝🌍speakers https://t.co/5758hOZEzZ support by: @SEinmunologia @SCImmunologia @EuMacDcSoc Sponsors: 🥇@miltenyibiotec 🥈@inmunotek 🥉@BioLegend @EMBO

Looking forward to welcoming everyone to beautiful Killarney for #KSMyeloidTargets24 with co-organizer @MaxKrummel, and discussing how academia & industry can align their efforts to develop effective myeloid cell targeted therapies for cancer.

Please, RT!!! 🚨DC lovers #DC2024Barcelona🚨 📅Abstract deadline approaching: SUBMIT NOW!!! 👇 https://t.co/ujuSt2Dk5q 34 slots for short talks available + posters! Supported by: @SEinmunologia @SCImmunologia @EuMacDcSoc Sponsors: 🥇@miltenyibiotec 🥈@inmunotek 🥉@BioLegend

Come check it out next Monday!

In the NYC/Philly area? Come learn about what's happening at @biorxivpreprint and SolvingFor! Join @MaxKrummel and @cshperspectives as they hit the road: NYU and Columbia on March 18th and UPenn on March 20th!

Very excited about this. Richard and I have a chance to share some pretty cool options to unleash science. Come check it out and try it out. Feels more like what we all came into science for… and a good product of all your collective minds.

I tried this out last week. It already feels much better as a reviewer when you are writing directly to the author and towards genuinely improving the quality of the science. It also is cognitively easier (and faster) to do a better job. This is going to be good.

Hope you can join @MaxKrummel and I at the keystone meeting we have organized on Myeloid Targeting Strategies for Cancer Treatment, this May in Killarney! https://t.co/AlCPn5eYmh #KSMyeloidTargets24

We are grateful to @FounderyInc. for their generosity and support of four ImmunoX fellows and for leading the charge in developing an innovative way to support the education of future scientists and ensure diversity, equity, and inclusion in science. #TheFutureisBright

Are so-called 'M2-like' CD206+ macrophages immunosuppressive? On the contrary, we find that they are critical for T cell mediated anti-tumor immunity https://t.co/XFOe4dknmL with @MaxKrummel @KenHu77 @KellyKersten8 @alexis_combes and others

‼️🚨Kick off your weekend with an intro to a new, journal-free system for publishing—developed by and for scientists—that we’re piloting with our friends in immunology. Feeling intrigued? fed-up? skeptical? rebellious? Come watch the pitch! 😎 https://t.co/n9th6bqIDz

Ten years ago, Miranda Broz first described rare CD103+ intratumoral DC (now:TucDC1) and their role in driving T cell responses. Here, @RayArja in the lab found the ID/signature of also-rare T cells that have exceptional effector responses. https://t.co/ZkGvhAvwPc Formative.

An anchoring aspect of this work is that tumors get their immune archetypes from one of the many normal functions of the immune system. Tumor immunity is no longer simply about 'immunity' v. tolerance. Join the team to build on this understanding, build it up, knock it down.

There are higher risks associated with development of new ideas. Foundery Immune Studios provides crucial preclinical infrastructure+capital to bolster confidence in the therapeutic potential of novel ideas and develop them into first-in-class drugs. I was happy to share the idea

In my experience, the most revolutionary scientific concepts face a high degree of skepticism from the venture community as they are supported by a limited number of experiments. Trapped in the 'therapeutic valley of death,' these ideas typically lie fallow in academia. 1/2

Our lab ( https://t.co/leZAONmnLs) is hiring a bioinformatics-minded person for the Immune Archetypes project.See it here: https://t.co/Yrz4p8lgso or apply here: https://t.co/2lM6v28tbU I'm so proud of our ambitious and professional crowd; join us in SF!

What a great thing for Seattle and the Allen Institute! We’ll miss Ananda in CA but we’re all also so happy for an awesome scientist, collaborator and person.

Passionate about driving scientific research and making an impact? We're hiring a Research Development Strategist & Grantwriter in the Bakar ImmunoX Initiative at UCSF. Apply now: https://t.co/ConyaWSbC1

Join us! SolvingFor is open to new members! Our first campaigns are launching, our new hire starts soon, and new member orientations begin as soon as July 6. Learn more about what it means to be a member, and how to sign up: